A Double-Blinded, Randomized, and Placebo-Controlled Phase 1 Study to Assess the Safety, Tolerability and Pharmacokinetics Profile of Single and Multiple Ascending Doses of FB2001 for Inhalation in Healthy Chinese Adults
Latest Information Update: 13 Jan 2023
At a glance
- Drugs Bofutrelvir (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Frontier Biotechnologies
Most Recent Events
- 09 Jan 2023 Status changed from not yet recruiting to completed.
- 20 Oct 2022 New trial record